- Home
- CEPU vs AGIO Comparison
CEPU vs AGIO Comparison
Compare CEPU & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- AGIO
- Stock Information
- Founded
- CEPU 1989
- AGIO 2007
- Country
- CEPU Argentina
- AGIO United States
- Employees
- CEPU N/A
- AGIO N/A
- Industry
- CEPU Electric Utilities: Central
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CEPU Utilities
- AGIO Health Care
- Exchange
- CEPU Nasdaq
- AGIO Nasdaq
- Market Cap
- CEPU 1.6B
- AGIO 1.4B
- IPO Year
- CEPU 2018
- AGIO 2013
- Fundamental
- Price
- CEPU $13.03
- AGIO $32.09
- Analyst Decision
- CEPU Hold
- AGIO Buy
- Analyst Count
- CEPU 1
- AGIO 8
- Target Price
- CEPU $12.00
- AGIO $56.00
- AVG Volume (30 Days)
- CEPU 366.8K
- AGIO 550.4K
- Earning Date
- CEPU 05-12-2025
- AGIO 05-01-2025
- Dividend Yield
- CEPU 2.38%
- AGIO N/A
- EPS Growth
- CEPU N/A
- AGIO N/A
- EPS
- CEPU 0.06
- AGIO 11.45
- Revenue
- CEPU $697,204,690.00
- AGIO $37,035,000.00
- Revenue This Year
- CEPU $26.57
- AGIO $27.43
- Revenue Next Year
- CEPU N/A
- AGIO $189.81
- P/E Ratio
- CEPU $22.04
- AGIO $2.80
- Revenue Growth
- CEPU N/A
- AGIO 25.96
- 52 Week Low
- CEPU $7.07
- AGIO $23.42
- 52 Week High
- CEPU $16.60
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CEPU 56.54
- AGIO 65.51
- Support Level
- CEPU $13.07
- AGIO $29.05
- Resistance Level
- CEPU $13.65
- AGIO $30.45
- Average True Range (ATR)
- CEPU 0.69
- AGIO 1.13
- MACD
- CEPU 0.02
- AGIO 0.33
- Stochastic Oscillator
- CEPU 52.99
- AGIO 91.98
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a private-sector power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.